Difference between revisions of "Degarelix (Firmagon)"
m |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with degarelix, in contrast to GnRH agonists.<ref name="insert">[http://www.firmagon.us/full_pi.pdf Degarelix (Firmagon) package insert]</ref><ref>[[Media:Degarelix.pdf | Degarelix (Firmagon) package insert (locally hosted backup)]]</ref> | + | Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with degarelix, in contrast to GnRH agonists.<ref name="insert">[http://www.firmagon.us/full_pi.pdf Degarelix (Firmagon) package insert]</ref><ref>[[Media:Degarelix.pdf | Degarelix (Firmagon) package insert (locally hosted backup)]]</ref><ref>[http://www.firmagon.us/ Firmagon manufacturer's website]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 12: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.firmagon.us/full_pi.pdf | + | *[http://www.firmagon.us/full_pi.pdf Degarelix (Firmagon) package insert]<ref name="insert"></ref> |
*[http://www.uptodate.com/contents/degarelix-patient-drug-information Degarelix (Firmagon) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/degarelix-patient-drug-information Degarelix (Firmagon) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/degarelix-patient-drug-information Degarelix (Firmagon) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/degarelix-patient-drug-information Degarelix (Firmagon) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | Degarelix acetate or FE200486. | ||
==References== | ==References== | ||
Revision as of 22:15, 22 January 2015
General information
Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with degarelix, in contrast to GnRH agonists.[1][2][3]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
Also known as
Degarelix acetate or FE200486.